alexa Progress in Copper Complexes as Anticancer Agents
ISSN: 2161-0444

Medicinal chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Progress in Copper Complexes as Anticancer Agents

Redouane Tabti1,2, Nassera Tounsi1, Christian Gaiddon3, Embarek Bentouhami2* and Laurent Désaubry1,4*

1Laboratory of Therapeutic Innovation (UMR 7200), Faculty of Pharmacy, University of Strasbourg - CNRS, Illkirch, France

2Faculty of Technology, University Ferhat Abbas, Sétif, Algeria

3UMR_S 1113, Molecular Mechanisms of Stress Response and Pathologies, INSERM, Strasbourg, France

4Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, 300457, China

*Corresponding Author:
Laurent Désaubry
Laboratory of Therapeutic Innovation (UMR 7200)
Faculty of Pharmacy, University of Strasbourg - CNRS, Illkirch, France
Tel: 33368854141
E-mail: [email protected]
Embarek Bentouhami
Faculty of Technology
University Ferhat Abbas, Sétif, Algeria,
Tel: 21336611194
E-mail: [email protected]

Received date: May 02, 2017; Accepted date: May 09, 2017; Published date: May 15, 2017

Citation: Tabti R, Tounsi N, Gaiddon C, Bentouhami E, Désaubry L (2017) Progress in Copper Complexes as Anticancer Agents. Med Chem (Los Angeles) 7: 139-143. doi: 10.4172/2161-0444.1000445

Copyright: © 2017 Tabti R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

The clinical success of cisplatin has stimulated the quest for novel anticancer metallodrugs during the last two decades. A major emphasis has been put on copper due to its selective cytotoxicity toward malignant cells. This selectivity stems from the hypoxic environment of cancer cells that promotes the reduction of Cu(II) to Cu(I), leading a pro-apoptotic oxidative stress. At the current time, two copper complexes have reached clinical assay, which paves the road to the first copper-based anticancer therapeutics.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords